amiodarone has been researched along with Death, Sudden in 68 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Death, Sudden: The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 9.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 7.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 7.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "Thirty-three consecutively referred patients with cardiac arrest from ventricular arrhythmias unassociated with a new acute myocardial infarction (AMI) were commenced on amiodarone therapy and followed for a minimum of 12 months." | 7.67 | Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone. ( Hamer, A; Mandel, WJ; Peter, T; Weiss, D, 1984) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 7.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "Ventricular arrhythmias represented 13% of the rhythmic indications." | 6.38 | The value of oral amiodarone in the treatment of ventricular arrhythmias in heart disease. ( Levy, S, 1991) |
| " The Authors evaluated the prophylactic efficacy of the chronic administration of amiodarone (A) on this arrhythmia and simultaneously the trend of ventricular extrasystole during the antiarrhythmic treatment." | 5.28 | [Amiodarone prophylaxis of ventricular tachycardia in ischemic cardiopathy]. ( Bernasconi, M; Cirino, D; Marzegalli, M; Pogna, M; Potenza, S, 1989) |
| "Nonetheless, arrhythmias in these patients were by no means abolished despite correction of these neuroendocrine and electrolyte abnormalities." | 5.27 | Arrhythmias in heart failure--the role of amiodarone. ( Cleland, JG; Dargie, HJ, 1988) |
| "The effects of long-term amiodarone therapy on the defibrillation thresholds and the rate of shocks were evaluated in 62 patients who had implantation of an automatic cardioverter-defibrillator (n = 53) or prophylactic implantation of patch electrodes (n = 9) who were survivors of sudden cardiac death (n = 34) or had refractory rapid ventricular tachycardia (n = 28)." | 5.07 | Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. ( Chenarides, JG; Huang, SK; Okike, NO; Tan de Guzman, WL; Vander Salm, TJ, 1991) |
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 5.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias." | 4.80 | Amiodarone: clinical trials. ( Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000) |
| "Despite the antiarrhythmic efficacy of amiodarone, a definitive correlation between amiodarone treatment and increased non-arrhythmic mortality in patients with heart failure and depressed ventricular function has been reported." | 4.80 | Perspectives: does amiodarone increase non-sudden deaths? If so, why? ( Auricchio, A; Klein, HU; Nisam, S, 2000) |
| " Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias." | 3.85 | Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. ( Fresno, M; Gironès, N; Marques, J; Mendoza, I; Mijares, A; Rodríguez-Angulo, H; Villegas, M, 2017) |
| "In patients with congestive heart failure on antiarrhythmic therapy, the SPAF trial has shown an increase in cardiac mortality and arrhythmic deaths." | 3.77 | Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint. ( Lévy, S, 1994) |
| "Thirty-three consecutively referred patients with cardiac arrest from ventricular arrhythmias unassociated with a new acute myocardial infarction (AMI) were commenced on amiodarone therapy and followed for a minimum of 12 months." | 3.67 | Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone. ( Hamer, A; Mandel, WJ; Peter, T; Weiss, D, 1984) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 3.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 3.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 3.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "An esophageal lead was used to perform decremental atrial pacing and elective induction of atrial fibrillation (AF) in 5 patients with the Wolff-Parkinson-White (W-P-W) syndrome before and after amiodarone therapy." | 3.66 | Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy. ( Coltorti, F; Condorelli, M; Critelli, G; Grassi, G; Monda, V; Perticone, F, 1983) |
| "Amiodarone treatment (loading dose 30 g given over 6 weeks; maintenance dose 400 mg/day) was prospectively evaluated in 50 patients with HC in whom the drug was initiated because of symptoms refractory to conventional drug therapy (calcium antagonists and beta blockers)." | 2.67 | Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. ( Bonow, RO; Cannon, RO; Epstein, SE; Fananapazir, L; Leon, MB; Tracy, CM, 1991) |
| "Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics." | 2.65 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982) |
| "The prevention of sudden death remains a key aspect of clinical management in patients with hypertrophic cardiomyopathy (HCM)." | 2.41 | The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. ( Elliott, PM, 2001) |
| "Patients with risk factors for sudden death, in particular those who have a severe impairment of left ventricular function and/or severe ischemia in the stress test, would be able to take advantage of a revascularization procedure when the culprit vessel remains occluded." | 2.39 | [Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction]. ( Arós Borau, F; Loma-Osorio, A; Torres Bosco, A, 1996) |
| "Ventricular arrhythmias represented 13% of the rhythmic indications." | 2.38 | The value of oral amiodarone in the treatment of ventricular arrhythmias in heart disease. ( Levy, S, 1991) |
| " It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracardiac, which are dependent upon dosage and duration of treatment." | 2.38 | Practical aspects of the use of amiodarone. ( Puech, P, 1991) |
| "This article discusses arrhythmias in hypertrophic and dilated cardiomyopathy in relation to clinical significance and treatment; when possible, the authors comment on etiology." | 2.37 | Arrhythmias in dilated and hypertrophic cardiomyopathy. ( Goodwin, JF; Krikler, DM; McKenna, WJ, 1984) |
| "A recent report has described sudden death of a horse following attempted conversion of SVT with oral flecainide acetate." | 1.46 | Treatment of supraventricular tachycardia in a horse. ( Blas-Machado, U; Coleman, AE; Credille, BC; Giguère, S; Maisenbacher, HW; Rapoport, GS; Tennent-Brown, BS; Whelchel, DD, 2017) |
| "With amiodarone, VT was no longer inducible or was more difficult to induce in 11 patients (31%), and the drug abolished VT during Holter monitoring in all patients." | 1.28 | Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. ( Epstein, SE; Fananapazir, L, 1991) |
| " The efficacy of amiodarone in cardiac arrhythmias is limited in chronic administration by the possibility of dose-dependent secondary effects." | 1.28 | [Amiodarone: a general antiarrhythmic agent]. ( Puech, P, 1990) |
| " The Authors evaluated the prophylactic efficacy of the chronic administration of amiodarone (A) on this arrhythmia and simultaneously the trend of ventricular extrasystole during the antiarrhythmic treatment." | 1.28 | [Amiodarone prophylaxis of ventricular tachycardia in ischemic cardiopathy]. ( Bernasconi, M; Cirino, D; Marzegalli, M; Pogna, M; Potenza, S, 1989) |
| " If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate." | 1.27 | New directions in antiarrhythmic drug therapy. ( Somberg, JC, 1984) |
| " The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing." | 1.27 | [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation]. ( Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984) |
| "Ventricular tachycardia is detected during electrocardiographic monitoring in 20 to 30% of patients; this arrhythmia is a sensitive but non-specific marker of those patients who are at particular risk of sudden death." | 1.27 | Arrhythmia and prognosis in hypertrophic cardiomyopathy. ( McKenna, WJ, 1983) |
| "The mechanisms underlying the cause of sudden death have not been clearly elucidated." | 1.27 | [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences]. ( Kleinebenne, A; McKenna, WJ, 1985) |
| "Nonetheless, arrhythmias in these patients were by no means abolished despite correction of these neuroendocrine and electrolyte abnormalities." | 1.27 | Arrhythmias in heart failure--the role of amiodarone. ( Cleland, JG; Dargie, HJ, 1988) |
| "A patient with clinically silent mitral valve prolapse experienced an episode of out-of-hospital cardiac arrest due to ventricular fibrillation." | 1.27 | Ventricular fibrillation in a patient with 'silent' mitral valve prolapse. ( Agmon, J; Caspi, A; Kusniec, J; Lewin, RF; Sclarovsky, S; Strasberg, B, 1988) |
| "65 patients with dilated cardiomyopathy underwent 24-hour electrocardiographic monitoring: 95." | 1.27 | [Ambulatory ECG in cardiomyopathies]. ( Camerini, F; Di Lenarda, A; Mestroni, L; Miani, D; Neri, R, 1987) |
| "Ventricular arrhythmias could be induced in 69% of patients with aborted sudden death but inducibility could be suppressed in only 20% of them." | 1.27 | Electrophysiologic testing and follow-up of patients with aborted sudden death. ( Eldar, M; Sauve, MJ; Scheinman, MM, 1987) |
| "The actuarial risk for sudden death in group B was 31% (95% confidence interval, 11% to 51%) at 1 and 2 years, a value that was significantly higher than that for group A (p less than 0." | 1.27 | The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. ( Elson, JJ; Fiedler, SB; Fogoros, RN, 1987) |
| "In all six patients with sudden death or recurrence of VT, the arrhythmia remained inducible on drug therapy." | 1.27 | Sustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy: electrophysiologic testing and lack of response to antiarrhythmic drug therapy. ( Buxton, AE; Doherty, JU; Josephson, ME; Marchlinski, FE; Poll, DS; Waxman, HL, 1984) |
| "Amiodarone therapy was initiated with a 5 mg/kg infusion followed by 600 to 800 mg/day for 7 to 10 days, then 200 to 400 mg/day." | 1.27 | Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity. ( Benaderet, D; Blevins, RD; Faitel, K; Garfinkel, C; Jarandilla, R; Kerin, NZ; Klein, S; Rubenfire, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (54.41) | 18.7374 |
| 1990's | 24 (35.29) | 18.2507 |
| 2000's | 4 (5.88) | 29.6817 |
| 2010's | 3 (4.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez-Angulo, H | 1 |
| Marques, J | 1 |
| Mendoza, I | 1 |
| Villegas, M | 1 |
| Mijares, A | 1 |
| Gironès, N | 1 |
| Fresno, M | 1 |
| Shah, R | 1 |
| Deam, AG | 1 |
| Whelchel, DD | 1 |
| Tennent-Brown, BS | 1 |
| Coleman, AE | 1 |
| Rapoport, GS | 1 |
| Blas-Machado, U | 1 |
| Maisenbacher, HW | 1 |
| Credille, BC | 1 |
| Giguère, S | 1 |
| Somberg, JC | 1 |
| Lüderitz, B | 1 |
| Manz, M | 1 |
| Steinbeck, G | 1 |
| Tuna, JL | 1 |
| Correia, MJ | 1 |
| d'Almeida, VC | 1 |
| Mourão, L | 1 |
| da Costa, FL | 1 |
| Ribeiro, C | 1 |
| Woosley, RL | 2 |
| Roden, DM | 3 |
| Duff, HJ | 1 |
| Oates, JA | 1 |
| McKenna, WJ | 4 |
| Krikler, DM | 1 |
| Goodwin, JF | 2 |
| Raviele, A | 1 |
| Di Pede, F | 1 |
| Delise, P | 1 |
| Piccolo, E | 1 |
| Patterson, E | 1 |
| Eller, BT | 1 |
| Abrams, GD | 1 |
| Vasiliades, J | 1 |
| Lucchesi, BR | 1 |
| Peter, T | 1 |
| Hamer, A | 1 |
| Weiss, D | 1 |
| Mandel, WJ | 1 |
| McGovern, B | 1 |
| Garan, H | 1 |
| Malacoff, RF | 1 |
| DiMarco, JP | 1 |
| Grant, G | 1 |
| Sellers, TD | 1 |
| Ruskin, JN | 1 |
| Poll, DS | 1 |
| Marchlinski, FE | 3 |
| Buxton, AE | 3 |
| Doherty, JU | 2 |
| Waxman, HL | 1 |
| Josephson, ME | 3 |
| Critelli, G | 1 |
| Grassi, G | 1 |
| Perticone, F | 1 |
| Coltorti, F | 1 |
| Monda, V | 1 |
| Condorelli, M | 1 |
| Maggioni, AP | 1 |
| Maggi, A | 1 |
| Volpi, A | 1 |
| D'Aranno, V | 1 |
| Tognoni, G | 1 |
| Giani, P | 1 |
| Lévy, S | 2 |
| Rapezzi, C | 1 |
| Spirito, P | 1 |
| Arós Borau, F | 1 |
| Loma-Osorio, A | 1 |
| Torres Bosco, A | 1 |
| Farré, J | 1 |
| Sim, I | 1 |
| McDonald, KM | 1 |
| Lavori, PW | 1 |
| Norbutas, CM | 1 |
| Hlatky, MA | 2 |
| Zamorski, M | 1 |
| Owens, DK | 1 |
| Connolly, SJ | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Auricchio, A | 1 |
| Nisam, S | 1 |
| Klein, HU | 1 |
| Elliott, PM | 1 |
| Sweeney, MO | 1 |
| Koch-Weser, J | 1 |
| Epstein, AE | 1 |
| Ellenbogen, KA | 1 |
| Kirk, KA | 1 |
| Kay, GN | 1 |
| Dailey, SM | 1 |
| Plumb, VJ | 1 |
| Peche, R | 1 |
| Abramowicz, M | 1 |
| Unger, J | 1 |
| Singh, BN | 1 |
| Puech, P | 2 |
| Katritsis, D | 1 |
| Camm, AJ | 1 |
| Huang, SK | 1 |
| Tan de Guzman, WL | 1 |
| Chenarides, JG | 1 |
| Okike, NO | 1 |
| Vander Salm, TJ | 1 |
| Gilligan, DM | 1 |
| Missouris, CG | 1 |
| Boyd, MJ | 1 |
| Oakley, CM | 1 |
| Scheinman, MM | 3 |
| Fananapazir, L | 2 |
| Leon, MB | 1 |
| Bonow, RO | 1 |
| Tracy, CM | 1 |
| Cannon, RO | 1 |
| Epstein, SE | 2 |
| Dorian, P | 1 |
| Nademanee, K | 1 |
| Burkart, F | 1 |
| Pfisterer, M | 1 |
| Kiowski, W | 1 |
| Follath, F | 1 |
| Burckhardt, D | 1 |
| Schmidt, SB | 1 |
| Katz, RJ | 1 |
| Gilbert, J | 1 |
| Gold, RL | 1 |
| Haffajee, CI | 1 |
| Alpert, JS | 1 |
| Kleinebenne, A | 1 |
| Goldstein, S | 1 |
| Mercereau, D | 1 |
| Kubac, G | 1 |
| Klinke, WP | 1 |
| Bernasconi, M | 1 |
| Pogna, M | 1 |
| Potenza, S | 1 |
| Marzegalli, M | 1 |
| Cirino, D | 1 |
| Wyndham, CR | 1 |
| Dargie, HJ | 1 |
| Cleland, JG | 1 |
| Strasberg, B | 1 |
| Caspi, A | 1 |
| Kusniec, J | 1 |
| Lewin, RF | 1 |
| Sclarovsky, S | 1 |
| Agmon, J | 1 |
| Popławska, W | 1 |
| Chlewicka, I | 1 |
| Wójcik, E | 1 |
| Paczkowski, D | 1 |
| Walczak, F | 1 |
| Podleśny, J | 1 |
| Mestroni, L | 1 |
| Miani, D | 1 |
| Neri, R | 1 |
| Di Lenarda, A | 1 |
| Camerini, F | 1 |
| Eldar, M | 1 |
| Sauve, MJ | 2 |
| Schmitt, C | 1 |
| Brachmann, J | 1 |
| Waldecker, B | 1 |
| Rizos, I | 1 |
| Senges, J | 1 |
| Kübler, W | 1 |
| Fogoros, RN | 1 |
| Fiedler, SB | 1 |
| Elson, JJ | 1 |
| Miller, JM | 1 |
| Vassallo, JA | 1 |
| Flores, BT | 1 |
| Roy, D | 1 |
| Kerin, NZ | 1 |
| Blevins, RD | 1 |
| Benaderet, D | 1 |
| Faitel, K | 1 |
| Jarandilla, R | 1 |
| Garfinkel, C | 1 |
| Klein, S | 1 |
| Rubenfire, M | 1 |
| DiCarlo, LA | 1 |
| Morady, F | 1 |
| Malone, P | 1 |
| Davis, JC | 1 |
| Evans-Bell, T | 1 |
| Winston, SA | 1 |
19 reviews available for amiodarone and Death, Sudden
| Article | Year |
|---|---|
Arrhythmias in dilated and hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomegaly; Cardiomyopathy, Hypertrophic; Death, Sudden; Electro | 1984 |
The natural history of hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Death, Sudden; Humans; Nifedipine; P | 1981 |
Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.
Topics: Amiodarone; Coronary Disease; Death, Sudden; Follow-Up Studies; Heart Failure; Humans; Sodium Channe | 1994 |
[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 1996 |
Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Female; Humans; Male; Middle Aged; Randomiz | 1997 |
Evidence-based analysis of amiodarone efficacy and safety.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden; Humans; Tachycardia, Ventric | 1999 |
Amiodarone: clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; D | 2000 |
Perspectives: does amiodarone increase non-sudden deaths? If so, why?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Death, Sudden, Cardiac; Female; Heart Failure; Hu | 2000 |
The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden; Defibrillators, Imp | 2001 |
Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part II.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden; Digoxin; Evidence-Based | 2001 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
Failure to respond to dexamethasone with fatal consequences, after initial response to multidrug treatment in a case of amiodarone-associated thyrotoxicosis.
Topics: Amiodarone; Angina, Unstable; Death, Sudden; Dexamethasone; Humans; Hyperthyroidism; Male; Middle Ag | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
The value of oral amiodarone in the treatment of ventricular arrhythmias in heart disease.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Death, Sudden; Heart Diseases; Humans | 1991 |
Practical aspects of the use of amiodarone.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Contraindications; Death, Sudden; Electrocar | 1991 |
Amiodarone in long term prophylaxis.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Death, Sudden; Electrophysiology; Heart Cond | 1991 |
Mechanisms and prevention of sudden death in coronary heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Death, Sudden; Humans | 1989 |
Role of invasive electrophysiologic testing in the management of life-threatening ventricular arrhythmias.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Electrophysiology; Heart | 1988 |
Pharmacologic therapy for survivors of sudden death based on programmed stimulation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden; Heart; Heart Arrest; | 1985 |
11 trials available for amiodarone and Death, Sudden
| Article | Year |
|---|---|
Procainamide, oxprenolol and amiodarone as antidysrhythmic drugs in myocardial infarction.
Topics: Amiodarone; Benzofurans; Cardiac Complexes, Premature; Clinical Trials as Topic; Death, Sudden; Doub | 1980 |
Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1982 |
Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.
Topics: Amiodarone; Coronary Disease; Death, Sudden; Follow-Up Studies; Heart Failure; Humans; Sodium Channe | 1994 |
Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Female; Humans; Male; Middle Aged; Randomiz | 1997 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Death, Sudden; Differential Thres | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator.
Topics: Amiodarone; Death, Sudden; Electric Countershock; Female; Follow-Up Studies; Humans; Male; Middle Ag | 1991 |
Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, Ambulatory; Fem | 1991 |
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Female; Humans; Male; Middl | 1990 |
Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Death, Sudden; Drug Evaluation; Drug Therapy, Combination; Female; Follow-U | 1986 |
42 other studies available for amiodarone and Death, Sudden
| Article | Year |
|---|---|
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Arrhythmias, Cardiac; Biomarkers; Chagas Disease; Cyt | 2017 |
Wide complex tachycardia in a patient with a family history of sudden death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Electrocardiography; Humans; Hypotension; Male; M | 2015 |
Treatment of supraventricular tachycardia in a horse.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Death, Sudden; Electric Countershock; Emergencies; Hors | 2017 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benz | 1984 |
[Sudden heart death in ventricular heart rhythm disorders: possibilities and limits of long-term therapy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Disopyramide; German | 1984 |
[Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Disopyramide; Drug Therapy, Combination; Electrocardiography | 1984 |
Ventricular fibrillation in a conscious canine preparation of sudden coronary death--prevention by short- and long-term amiodarone administration.
Topics: Amiodarone; Animals; Benzofurans; Consciousness; Coronary Disease; Death, Sudden; Dogs; Electrocardi | 1983 |
Arrhythmia and prognosis in hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; | 1983 |
Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Death, Sudden; Dose-Response Relationshi | 1984 |
Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Femal | 1984 |
Sustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy: electrophysiologic testing and lack of response to antiarrhythmic drug therapy.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Death, Sudden; Electric St | 1984 |
Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy.
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Cardiac Pacing, Artificial; Death, Sudden; Esoph | 1983 |
Amiodarone distribution in human tissues after sudden death during Holter recording.
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Death, Sudden; Electrocardiography; Humans; Male; Mid | 1983 |
[Complex and asymptomatic hyperkinetic ventricular arrhythmias: a daily difficult decision problem].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Card | 1994 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
[Implantable automatic defibrillator after MADIT and EMIAT].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden; Defibrillators, Implant | 1996 |
Amiodarone and mortality in CHF and post-MI.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Heart Failure; Human | 1998 |
Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Death, Sudden; Deci | 1998 |
Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, A | 1991 |
Invasive electrophysiologic studies as predictor of sudden death and for treatment of patients with aborted sudden death.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Child; Death, Sudden; Electric Cou | 1990 |
Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Death, S | 1991 |
Designing clinical trials in the post CAST era--where do we go from here?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; F | 1991 |
The amiodarone--class I agent combination increases refractoriness, conduction, and the number of electrophysiologic studies. But does it increase survival rate?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Drug Synergism; Drug Therapy, Combination; Tachyc | 1991 |
[Amiodarone: a general antiarrhythmic agent].
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Heart; Humans; Sympathetic Ner | 1990 |
PVCs in the elderly: when to start worrying.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Electrocardio | 1985 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action | 1985 |
Sudden cardiac death in a southeast Asian immigrant: clinical, electrophysiologic, and biopsy characteristics.
Topics: Adult; Amiodarone; Cambodia; Death, Sudden; Electrocardiography; Humans; Male; Refugees; United Stat | 1986 |
QT prolongation and arrhythmia suppression.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Deafness; Death, Sudden; Elect | 1985 |
[Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Pr | 1985 |
[Multicenter clinical trial on the prevention of sudden death after myocardial infarction by the use of anti-arrhythmia agents. Investigator Group of the Spanish Study on Sudden Death].
Topics: Amiodarone; Arrhythmias, Cardiac; Captopril; Death, Sudden; Humans; Metoprolol; Multicenter Studies | 1989 |
Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden; Exercise Test; Humans; Male; Ventric | 1989 |
[Amiodarone prophylaxis of ventricular tachycardia in ischemic cardiopathy].
Topics: Aged; Aged, 80 and over; Amiodarone; Coronary Disease; Death, Sudden; Electrocardiography; Female; H | 1989 |
[Symposium: Sudden cardiac death. The importance of amiodarone in the treatment of life-threatening arrhythmia. Munich, 10-11 June 1988].
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden; Heart Arrest; Humans | 1988 |
Arrhythmias in heart failure--the role of amiodarone.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden; Female; Follow-Up Studies; Heart Failure; Hum | 1988 |
Ventricular fibrillation in a patient with 'silent' mitral valve prolapse.
Topics: Adult; Amiodarone; Death, Sudden; Drug Therapy, Combination; Electrophysiology; Follow-Up Studies; H | 1988 |
[Remote results of the pharmacological treatment of patients with a high risk of sudden heart arrest in ventricular disorders of cardiac rhythm].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Female; Heart Arrest; Humans; Male; Mexiletine; Middle Aged; | 1987 |
[Ambulatory ECG in cardiomyopathies].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiomyopathy, Dilated; | 1987 |
Electrophysiologic testing and follow-up of patients with aborted sudden death.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Catheteri | 1987 |
Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Female; Follow-Up Studie | 1987 |
The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias.
Topics: Aged; Amiodarone; Combined Modality Therapy; Death, Sudden; Drug Resistance; Electric Countershock; | 1987 |
Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity.
Topics: Aged; Amiodarone; Benzofurans; Coronary Disease; Death, Sudden; Drug Evaluation; Electrocardiography | 1986 |
Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
Topics: Aged; Amiodarone; Analysis of Variance; Benzofurans; Death, Sudden; Female; Heart Arrest; Humans; Ma | 1985 |